Braveheart Investment Group (AIM: BRH), is pleased to provide an operations update on Phasefocus Holdings Limited (“Phasefocus”), the computational imaging technology company in which Braveheart owns 42.67 per cent. of the issued share capital.
The Phasefocus Virtual Lens™ is a novel method for high fidelity quantitative phase imaging and microscopy that has a wide range of applications including live-cell imaging, engineering metrology and electron microscopy.
The switch to online sales meetings and virtual demonstrations for its high-value instrument is proving successful. With life science research laboratories working hard throughout the pandemic Phasefocus continues to have a strong sales pipeline for Livecyte2™ instruments and received orders from customers in Italy, Israel and China, as well as software and hardware upgrades to existing Livecyte™ users at York, Manchester and Hull Universities, the Francis Crick Institute and others.
As well as original equipment sales to customers, Phasefocus is seeing a growing demand for long term service contracts. Phasefocus sees this as an excellent opportunity to increase guaranteed revenues, whilst providing users with certainty that they continue to operate at the forefront of the scientific capability, through regular system updates and servicing.
The Livecyte2™ software is already a market leader enabling users to record, track and classify the responses of individual live cells, grown in the laboratory, as they are subjected to drugs. Phasefocus is now working, in collaboration with the Manchester University, to further enhance LiveCyte™ using Artificial Intelligence (“AI”) based image classification.
About RNS Reach announcements
This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned